Rallybio is developing therapeutic candidates for the treatment of patients with severe and rare immuno-inflammatory diseases. Additional information on these candidates and the disease targets will be available as development progresses.
Rallybio is developing therapeutic candidates for the treatment of patients with severe and rare immuno-inflammatory diseases. Additional information on these candidates and the disease targets will be available as development progresses.